Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies.

Zachary A Yetmar Ryan B KhodadadiMaria Teresa SevilleLisa M Brumble John C O'Horo Ravindra Ganesh Raymund R Razonable

Published in: Open forum infectious diseases (2022)

Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.

Keyphrases

coronavirus disease
mechanical ventilation
monoclonal antibody
respiratory syndrome coronavirus
acute respiratory distress syndrome
respiratory failure
intensive care unit
sars cov
metabolic syndrome
extracorporeal membrane oxygenation
adipose tissue